Intrinsic Therapeutics Inc. closed a $52 million series growth equity financing led by Questa Capital. Intrinsic's Barricaid Anular Closure device received premarket approval from the U.S. FDA in February and the funds will be used to propel the device's strategic market release, according to the Woburn, Mass.-based company. Returning investors in this round included New Enterprise Associates, Greenspring Associates, Quadrille and Delos Capital. Read More
